Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Development Of Immunosuppressant Drugs
3.2. Market Definition
3.3. Key Drivers
3.3.1. Increase In The Number Of Autoimmune Disorders
3.3.2. Rise In Organ Transplantation
3.3.3. Growth In The Pharmaceutical Industry
3.4. Key Restraints
3.4.1. Side Effects Of Immunosuppressant Drugs
3.4.2. Lack Of Awareness About Organ Donation

4. Key Analytics
4.1. Key Investment Insights
4.2. Porter’S Five Force Analysis
4.2.1. Buyer Power
4.2.2. Supplier Power
4.2.3. Substitution
4.2.4. New Entrants
4.2.5. Industry Rivalry
4.3. Opportunity Matrix
4.4. Vendor Landscape

5. Market By Distribution Channel
5.1. Hospital Pharmacies
5.2. Retail Pharmacies
5.3. Online Pharmacies

6. Market By End-User
6.1. Organ Transplantation
6.2. Autoimmune Disorders
6.3. Others

7. Market By Drug Class
7.1. Corticosteroids
7.2. Monoclonal Antibodies
7.3. Calcineurin Inhibitors
7.4. Mtor Inhibitors
7.5. Others

8. Geographical Analysis
8.1. Europe
8.1.1. United Kingdom
8.1.2. Germany
8.1.3. France
8.1.4. Italy
8.1.5. Russia
8.1.6. Belgium
8.1.7. Poland
8.1.8. Rest Of Europe

9. Company Profiles
9.1. Abbvie Inc
9.2. Allergan Plc (Acquired By Abvie Inc)
9.3. Astellas Pharma Inc
9.4. Bristol-Myers Squibb Company
9.5. Cipla Ltd
9.6. Dr. Reddy’S Laboratories Ltd
9.7. F Hoffmann-La Roche Ag
9.8. Glaxosmithkline Plc
9.9. Intas Pharmaceuticals Ltd (Accord Healthcare Ltd)
9.10. Janssen Pharmaceuticals Nv (Jhonson & Jhonson)
9.11. Mylan Nv
9.12. Novartis International Ag (Sandoz)
9.13. Pfizer Inc
9.14. Sanofi Sa
9.15. Veloxis Pharmaceuticals



List of Figures


Figure 1: Development Of Immunosuppressant Drugs
Figure 2: Key Investment Insights
Figure 3: Porter’S Five Force Analysis
Figure 4: Opportunity Matrix
Figure 5: Vendor Landscape
Figure 6: Europe Immunosuppressant Drugs Market, Growth Potential, By Distribution Channel, In 2019
Figure 7: Europe Immunosuppressant Drugs Market, By Hospital Pharmacies, 2019-2028 (In $ Million)
Figure 8: Europe Immunosuppressant Drugs Market, By Retail Pharmacies, 2019-2028 (In $ Million)
Figure 9: Europe Immunosuppressant Drugs Market, By Online Pharmacies, 2019-2028 (In $ Million)
Figure 10: Europe Immunosuppressant Drugs Market, Growth Potential, By End-User, In 2019
Figure 11: Europe Immunosuppressant Drugs Market, By Organ Transplantation, 2019-2028 (In $ Million)
Figure 12: Europe Immunosuppressant Drugs Market, By Autoimmune Disorders, 2019-2028 (In $ Million)
Figure 13: Europe Immunosuppressant Drugs Market, By Others, 2019-2028 (In $ Million)
Figure 14: Europe Immunosuppressant Drugs Market, Growth Potential, By Class, In 2019
Figure 15: Europe Immunosuppressant Drugs Market, By Corticosteroids, 2019-2028 (In $ Million)
Figure 16: Europe Immunosuppressant Drugs Market, By Monoclonal Antibodies, 2019-2028 (In $ Million)
Figure 17: Europe Immunosuppressant Drugs Market, By Calcineurin Inhibitors, 2019-2028 (In $ Million)
Figure 18: Europe Immunosuppressant Drugs Market, By Mtor Inhibitors, 2019-2028 (In $ Million)
Figure 19: Europe Immunosuppressant Drugs Market, By Others, 2019-2028 (In $ Million)
Figure 20: Europe Immunosuppressant Drugs Market, Regional Outlook, 2018 & 2028 (In %)
Figure 21: United Kingdom Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 22: Germany Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 23: France Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 24: Italy Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 25: Russia Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 26: Belgium Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 27: Poland Immunosuppressant Drugs Market, 2019-2028 (In $ Million)
Figure 28: Rest Of Europe Immunosuppressant Drugs Market, 2019-2028 (In $ Million)


List of Tables


TABLE 1: MARKET SNAPSHOT - IMMUNOSUPPRESSANT DRUGS
TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
TABLE 4: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 6: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 8: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 9: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 10: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 11: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)